Pyxis Oncology Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company focused on developing next-generation cancer therapies. By harnessing the power of antibody-drug conjugates (ADCs) and immuno-oncology approaches, the company aims to create targeted treatments that improve outcomes for cancer patients. With a commitment to scientific innovation and precision medicine, Pyxis Oncology is advancing a pipeline of novel therapies designed to enhance the effectiveness and safety of cancer treatments. As it progresses through clinical trials, the company remains dedicated to transforming oncology care with cutting-edge biopharmaceutical solutions.
Latest shares articles
Magnificent Seven Earnings Review
The Q1 2025 earnings season for the Magnificent Seven—Apple, Microsoft, Nvidia, Amazon, Alphabet, Meta Platforms, and Tesla—revealed a shared strategic emphasis on artificial intelligence, infrastructure investment, supply chain resilience, and capital discipline.
09:14, 3 June 2025
UK economy outpaces gloomy forecasts, yet caution remains
The UK economy grew more than expected in Q1 despite warnings about a recession, but the outlook remains clouded by the threat of tariffs
08:08, 15 May 2025
Barrick Gold forecast: Third-party price target
Discover the Barrick Gold (GOLD) price predictions for 2025 and beyond, with analyst price targets and more on Capital.com
15:41, 8 May 2025
US stocks hold ground despite Powell’s stagflation warning
US equities continue to attract buying interest backed by improved market sentiment despite Powell's warning about stagflation
11:29, 8 May 2025
Ratings and Reviews
Ratings and Reviews
